Jamani Kareem, He Qianchuan, Liu Yang, Davis Chris, Hubbard Jesse, Schoch Gary, Lee Stephanie J, Gooley Ted, Flowers Mary E D, Cheng Guang-Shing
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Biol Blood Marrow Transplant. 2020 May;26(5):943-948. doi: 10.1016/j.bbmt.2019.12.002. Epub 2019 Dec 9.
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (allo-HCT) is often diagnosed at a late stage when lung dysfunction is severe and irreversible. Identifying patients early after transplantation may offer improved strategies for early detection that could avert the morbidity and mortality of BOS. This study aimed to determine whether a decline in lung function before and early after (days +80 to +100) allo-HCT are associated with a risk of BOS beyond 6 months post-transplantation. In a single-center cohort of 2941 allo-HCT recipients, 186 (6%) met National Institutes of Health criteria for BOS. Pretransplantation and post-transplantation day +80 spirometric parameters were analyzed as continuous variables and included in a multivariable model with other factors, including donor source, graft source, conditioning regimen, use of total body irradiation, and immunoglobulin levels. Pre-transplantation forced expiratory flow between 25% and 75% of maximum (FEF), day +80 forced expiratory volume in 1 second (FEV), and day +80 FEF had the strongest associations with increased risk of BOS. Assessment of the multivariable model showed that a decline in day +80 FEF added additional risk to the day +80 FEV model (P = .03), whereas FEV decline at day +80 added no additional risk to the day +80 FEF model (P = .645). Moreover, day +80 FEF conferred additional risk when considered with pretransplantation FEF. These results suggest that day +80 FEF may be more important than FEV in predicting the development of BOS. This study highlights the importance of obtaining early post-transplantation pulmonary function tests for the potential risk stratification of patients at risk for BOS.
异基因造血细胞移植(allo-HCT)后闭塞性细支气管炎综合征(BOS)通常在肺功能严重且不可逆的晚期才被诊断出来。在移植后早期识别患者可能会提供更好的早期检测策略,从而避免BOS的发病和死亡。本研究旨在确定allo-HCT前及移植后早期(第80天至第100天)肺功能下降是否与移植后6个月以上发生BOS的风险相关。在一个单中心队列中,有2941名allo-HCT受者,其中186名(6%)符合美国国立卫生研究院BOS标准。将移植前和移植后第80天的肺量计参数作为连续变量进行分析,并纳入一个多变量模型,该模型包含其他因素,包括供体来源、移植物来源、预处理方案、全身照射的使用以及免疫球蛋白水平。移植前最大呼气流量25%至75%之间的用力呼气流量(FEF)、第80天1秒用力呼气量(FEV)和第80天FEF与BOS风险增加的关联最强。多变量模型评估显示,第80天FEF下降给第80天FEV模型增加了额外风险(P = 0.03),而第80天FEV下降未给第80天FEF模型增加额外风险(P = 0.645)。此外,将第80天FEF与移植前FEF一起考虑时,第80天FEF会带来额外风险。这些结果表明,在预测BOS的发生方面,第80天FEF可能比FEV更重要。本研究强调了进行移植后早期肺功能测试对于有BOS风险患者进行潜在风险分层的重要性。